Literature DB >> 16741885

Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.

Ebbing Lautenbach1, Neil O Fishman, Joshua P Metlay, Xiangqun Mao, Warren B Bilker, Pam Tolomeo, Irving Nachamkin.   

Abstract

BACKGROUND: The prevalence of fecal colonization with Escherichia coli that has reduced susceptibility to fluoroquinolones is unknown. A detailed characterization of such isolates is limited.
METHODS: We conducted 3 annual fecal surveillance initiatives at 2 hospitals from 2002 to 2004. All E. coli isolates with reduced susceptibility to fluoroquinolones (minimum inhibitory concentration [MIC] to levofloxacin, > or = 0.125 microg/mL) were identified. We characterized gyrA and parC mutations and organic solvent tolerance (OST). Isolates were compared using pulsed-field gel electrophoresis.
RESULTS: Of 789 fecal samples, 149 (18.9%) revealed E. coli with reduced susceptibility to fluoroquinolones. Of 149 isolates, 102 (68.5%) had a MIC > or = 8 microg/mL, 138 (92.6%) had > or = 1 gyrA mutation, 101 (67.8%) had > or = 1 parC mutation, and 59 (39.6%) demonstrated OST. Isolates with a MIC > or = 8 versus <8 microg/mL had more target mutations (median, 3 vs. 1; P<.001) and more often exhibited OST (51% vs. 15%; P<.001). Of 149 isolates, 144 (96.6%) demonstrated a MIC > or = 16 microg/mL to nalidixic acid. The prevalence of OST differed across study years (P = .01). There was no clonal spread of isolates.
CONCLUSIONS: Colonization by E. coli with reduced fluoroquinolone susceptibility is common, and fluoroquinolone-resistance characteristics differ significantly over time. Resistance to nalidixic acid may be useful in the identification of E. coli with early resistance mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741885     DOI: 10.1086/503046

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Effect of six fluoroquinolones on the expression of four efflux pumps in the multidrug resistant Escherichia coli isolates.

Authors:  Haixia Liu; Xiaoqiang Liu; Yinqian Li; Caiju Hao
Journal:  World J Microbiol Biotechnol       Date:  2015-04-09       Impact factor: 3.312

2.  Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli.

Authors:  Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Warren B Bilker; Ebbing Lautenbach
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

3.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

4.  The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Xiangqun Mao; Xiaoyan Han; Neil O Fishman; Warren B Bilker; Pam Tolomeo; Mary Wheeler; Irving Nachamkin
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany.

Authors:  M Kresken; K Becker; H Seifert; E Leitner; B Körber-Irrgang; C von Eiff; P-A Löschmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-24       Impact factor: 3.267

Review 6.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

7.  In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.

Authors:  Lorenzo Drago; Lucia Nicola; Roberto Mattina; Elena De Vecchi
Journal:  BMC Microbiol       Date:  2010-04-21       Impact factor: 3.605

8.  Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones.

Authors:  Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Warren B Bilker; Ebbing Lautenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-27       Impact factor: 2.803

9.  Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Mark G Weiner; Warren B Bilker; Pam Tolomeo; Xiangqun Mao; Irving Nachamkin; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

10.  Increasing resistance in commensal Escherichia coli, Bolivia and Peru.

Authors:  Alessandro Bartoloni; Lucia Pallecchi; Costanza Fiorelli; Tiziana Di Maggio; Connie Fernandez; Ana Liz Villagran; Antonia Mantella; Filippo Bartalesi; Marianne Strohmeyer; Angela Bechini; Herlan Gamboa; Hugo Rodriguez; Charlotte Kristiansson; Göran Kronvall; Eduardo Gotuzzo; Franco Paradisi; Gian Maria Rossolini
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.